Instil Bio, Inc.
|Company Name||Instil Bio, Inc.|
On October 31, 2022, before market hours, Instil Bio announced that it was voluntarily pausing enrollment in ongoing clinical trials due to “a recent decrease in the rate of successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured.”
On this news, Instil Bio’s stock fell $1.95, or 37.1%, to close at $3.30 per share on October 31, 2022, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Instil Bio, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.